公开(公告)号：EP3043179B1

公开(公告)日：2020-05-06

申请号：EP16156432.3

申请日：2010-04-01

申请人： Galapagos N.V.

发明人： BRYS, Reginald Christophe Xavier ,  NELLES, Luc ,  VANDEGHINSTE, Nick Ernest René ,  MILLE-BAKER, Blandine ,  TESSARI, Michela Angela

IPC分类号： G01N33/50 ,  G01N33/68 ,  C12N15/113

公开(公告)号：EP3043179A1

公开(公告)日：2016-07-13

申请号：EP16156432.3

申请日：2010-04-01

申请人： Galapagos N.V.

发明人： BRYS, Reginald Christophe Xavier ,  NELLES, Luc ,  VANDEGHINSTE, Nick Ernest René ,  MILLE-BAKER, Blandine ,  TESSARI, Michela Angela

IPC分类号： G01N33/50 ,  G01N33/68 ,  C12N15/113

摘要： The invention relates to the field of medicinal research, cartilage physiology and diseases involving the degeneration of cartilage tissue. More specifically, the invention relates to methods and means for identifying compounds that inhibit catabolic processes in chondrocytes and that decrease the degradation of cartilage and/or ECM. The invention also relates to the compounds that are useful in the treatment of osteoarthritis. The invention also relates to targets, the modulation of which results in a decrease in the degradation of ECM and /or cartilage and decrease inflammation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by the degradation of ECM and /or cartilage and inflammation.

摘要翻译： 本发明涉及医学研究，软骨生理学和涉及软骨组织退化的疾病领域。 更具体地，本发明涉及用于鉴定抑制软骨细胞分解代谢过程并降低软骨和/或ECM降解的化合物的方法和手段。 本发明还涉及可用于治疗骨关节炎的化合物。 本发明还涉及靶的调节，其导致ECM和/或软骨的降解降低并减少炎症。 此外，本发明涉及用于治疗以ECM和/或软骨和炎症降解为特征的病症的组合物和方法。

公开(公告)号：EP2414829A1

公开(公告)日：2012-02-08

申请号：EP10712085.9

申请日：2010-04-01

申请人： Galapagos N.V.

发明人： BRYS, Reginald Christophe Xavier ,  NELLES, Luc ,  VANDEGHINSTE, Nick Ernest Rene ,  MILLE-BAKER, Blandine ,  TESSARI, Michela Angela

IPC分类号： G01N33/50

CPC分类号： C12N15/1137 ,  C12N15/113 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/5032 ,  G01N33/6887 ,  G01N2333/726 ,  G01N2333/912 ,  G01N2333/9121 ,  G01N2333/96486 ,  G01N2333/96494 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2500/20 ,  G01N2800/105

摘要： The invention relates to the field of medicinal research, cartilage physiology and diseases involving the degeneration of cartilage tissue. More specifically, the invention relates to methods and means for identifying compounds that inhibit catabolic processes in chondrocytes and that decrease the degradation of cartilage and/or ECM. The invention also relates to the compounds that are useful in the treatment of osteoarthritis. The invention also relates to targets, the modulation of which results in a decrease in the degradation of ECM and /or cartilage and decrease inflammation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by the degradation of ECM and /or cartilage and inflammation.